
|Articles|May 1, 2003
ISTA to try again after FDA panel rejects Vitrase
Irvine, CA-ISTA Pharmaceuticals is regrouping after an FDA advisory committee said the company's tests of ovine hyal-uronidase (Vitrase) failed to demonstrate sufficient statistical evidence to support its efficacy in treating vitreous hemorrhage.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement

















